Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.

This study found that innate lymphoid cells-type 1 (ILC1) can induce alopecia areata by disrupting hair follicle immune privilege without the involvement of classical CD8+ T cells.

This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.

In this case-control study, individuals with alopecia areata showed significantly elevated levels of inflammatory markers IL-4, IFN-γ, and CRP, as well as reduced serum Folate and Ferritin, suggesting the condition's multifactorial pathophysiology involves immune activation, systemic inflammation, and micronutrient deficiencies.

This study identified dual epithelial and mesenchymal traits in dermal sheath cells during wound repair, suggesting they could be targeted to enhance healing.

This study found that pro-inflammatory cytokines and apoptotic mechanisms, specifically involving granzyme B and Fas pathways, are associated with chronic alopecia areata, indicating their potential role in the disease's persistence.

This review identifies shared interferon gamma-driven immune pathways in vitiligo and alopecia areata, revealing potential targets for new treatments, but reports no clinical results.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

This study found that specific gene upregulations and mutations in hidradenitis suppurativa skin support the role of inflammation, altered epithelial differentiation, and metabolism dysregulation in the disease's pathogenesis.

Harris et al. describe a new mouse model for vitiligo, where interfollicular melanocytes are retained and melanocyte-targeting immune responses are simulated, aiding the development of immunomodulatory therapies.

This chapter reviews recent developments in vitiligo research, highlighting the role of melanocyte stem cell differentiation and oxidative stress in its management, but reports no new clinical results.

This study developed and analyzed a mathematical model for alopecia areata involving interactions among immune cells and cytokines, establishing conditions under which hairless patches can become stable and pervasive, particularly with certain biological rate levels and chemotactic sensitivities.

This study found that α-melanocyte-stimulating hormone may modulate inflammation in skin connective tissue by inhibiting proinflammatory effects in fibroblasts.

In this study, researchers found that the protein eIF4E is crucial for keratinocyte proliferation in psoriasis, suggesting it as a potential treatment target for the condition.

This study demonstrates that T-cell responses in extensive alopecia areata scalp may be aberrantly regulated, with reduced cytokine production but activated phenotype, providing insight into the disease's immune mechanisms.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

This study found that topical application of Astragalus membranaceus extract induced hair regrowth and reduced immune response markers in mice with natural hair loss.

The authors concluded that increasing regulatory T cells in patients with alopecia areata may improve hair follicle regeneration by reducing autoimmune responses, suggesting a potential new therapeutic approach since current treatments are often ineffective with high relapse rates.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

This study suggests that αMSH may play a regulatory role in human dermal papilla cells, potentially influencing immune and inflammatory responses in hair follicles, which could contribute to inflammatory alopecia.

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.

This study found that topical ginsenoside Rg1 may protect skin from UVB-induced damage in mice by reducing pathological changes and modulating cytokine mRNA expression associated with inflammation and immune response.

In this study, researchers identified unique prenatal lymphocyte features in human fetal skin, including proliferative naive T cells and memory-like T cells, which may influence antigen and allergen responses in utero and infancy.

This study reported that CCT oligodeoxynucleotide induced patchy hair loss in male mice with specific genetic traits, suggesting gender and genetic preferences in immune response.

This study identified at least four distinct fibroblast populations in adult human skin, each with unique functional properties, suggesting potential therapeutic applications for wound healing and fibrosis-related diseases.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

This study found that certain T cell-associated genes were upregulated in dogs with Vogt-Koyanagi-Harada syndrome and vitiligo, suggesting a shared immunopathogenesis with humans.

This study suggests that SOCS3 treatment may effectively inhibit alopecia areata by suppressing CD8+ T cell activity and IFN-γ production.